MAGP2 Controls Notch via Interactions with RGD Binding Integrins: Identification of a Novel ECM-Integrin-Notch Signaling Axis by Deford, Peter et al.
Boise State University
ScholarWorks
Biology Faculty Publications and Presentations Department of Biological Sciences
2-1-2016
MAGP2 Controls Notch via Interactions with
RGD Binding Integrins: Identification of a Novel
ECM-Integrin-Notch Signaling Axis
Peter Deford
Boise State University
Kasey Brown
Indiana State University
Rae Lee Richards
Indiana State University
Aric King
Indiana State University
Kristin Newburn
Indiana State University
See next page for additional authors
This is an author-produced, peer-reviewed version of this article. © [YEAR], [PUBLISHER NAME]. Licensed under the Creative Commons [insert
license details and URL]. Details regarding the use of this work can be found at: http://creativecommons.org/licenses/[ENTER LICENSE
CODE]/[Version Number]/ . The final, definitive version of this document can be found online at [ JOURNAL NAME], doi: [DOI #]
Authors
Peter Deford, Kasey Brown, Rae Lee Richards, Aric King, Kristin Newburn, Katherine Westover, and Allan R.
Albig
This article is available at ScholarWorks: http://scholarworks.boisestate.edu/bio_facpubs/455
MAGP2 controls Notch via interactions with RGD binding integrins:  Identification of a 1 
Novel ECM – Integrin – Notch Signaling Axis. 2 
 3 
Peter Deford2,*, Kasey Brown3, Rae Lee Richards3, Aric King3, Kristin Newburn3, 4 
Katherine Westover2, and Allan R. Albig1,2,# 5 
 6 
1Biomolecular Sciences PhD Program, Boise State University, Boise, ID.  83725 7 
2Dept. of Biology, Boise State University, Boise, ID.  83725 8 
3Dept. of Biology, Indiana State University, Terre Haute, IN.  47809 9 
 10 
Running Title:  ECM controls Notch via Integrins 11 
 12 
Keywords:  Extracellular matrix, cell signaling, Notch, Integrin 13 
 14 
#Address correspondence to Allan R. Albig. AllanAlbig@boisestate.edu 15 
*Present Address: Peter Deford, Dept. of Cell, Molecular, Developmental Biology, and 16 
Biophysics, Johns Hopkins University. 17 
 18 
Abbreviations: 19 
MAGP2 – Microfibril Associated Glycoprotein 2 20 
N1ICD – Notch1 Intracellular domain 21 
ECM – Extracellular Matrix 22 
HMEC – Human Microvascular Endothelial cells 23 
 24 
 25 
 26 
  27 
Abstract: Canonical Notch signaling involves Notch receptor activation via interaction 28 
with cell surface bound Notch ligand.  Recent findings also indicate that Notch signaling 29 
may be modulated by cross-talk with other signaling mechanisms.  The ECM protein 30 
MAGP2 was previously shown to regulate Notch in a cell type dependent manner, 31 
although the molecular details of this interaction have not been dissected.  Here, we 32 
report that MAGP2 cell type specific control of Notch is independent of individual Notch 33 
receptor-ligand combinations but dependent on interaction with RGD binding integrins.  34 
Overexpressed MAGP2 was found to suppress transcriptional activity from the Notch 35 
responsive Hes1 promoter activity in endothelial cells, while overexpression of a 36 
RGDRGE MAGP2 mutant increased Notch signaling in the same cell type.  This effect 37 
was not unique to MAGP2 since the RGD domain of the ECM protein EGFL7 was also 38 
found to be an important modulator of Hes1 promoter activity.  Independently of MAGP2 39 
or EGFL7, inhibition of RGD-binding integrins with soluble RGD peptides also 40 
increased accumulation of active N1ICD fragments and Notch responsive promoter 41 
activity independently of changes in Notch1, Jag1, or Dll4 expression.  Finally, β1 or β3 42 
integrin blocking antibodies also enhanced Notch signaling.  Collectively, these results 43 
answer the question of how MAGP2 controls cell type dependent Notch signaling, but 44 
more importantly uncover a new mechanism to understand how extracellular matricies 45 
and cellular environments impact Notch signaling. 46 
 47 
 48 
  49 
 50 
 51 
 52 
  53 
Introduction: 54 
 55 
Extracellular matrices within cellular microenvironments play an integral role in the 56 
regulation of a wide variety of normal cellular physiological responses.  Alternatively, 57 
abnormal extracellular microenvironments contribute to the pathogenesis of many 58 
vascular diseases of humans such as atherosclerosis, arteriosclerosis, and cancer.  59 
Therefore understanding how ECM molecules in these diverse microenvironments 60 
impact cell physiology is an important step towards to understanding the pathophysiology 61 
of these diseases. 62 
 63 
There are numerous receptor mechanisms whereby cells detect and interact with ECM 64 
molecules within cellular microenvironments.  The best understood of these cellular 65 
ECM receptor systems are integrins which are heterodimeric transmembrane proteins 66 
consisting of one α-subunit and one β-subunit.  Collectively, there are 18 known α-67 
subunits and 8 known β-subunits that can combine in various combinations to form up to 68 
24 functional integrins [1].  Integrin heterodimers have diverse ligand specificities 69 
including the arginine-glycine-aspartic acid (RGD) domain [2].  Once bound to specific 70 
ECM ligands, integrins initiate a wide variety of signaling cascades that are mediated by 71 
activation of several downstream kinases including focal adhesion kinase (FAK), Src, 72 
and the integrin-linked kinase (ILK) pathways that collectively have broad impacts on 73 
cellular physiology [3]. 74 
 75 
Microfibril associated glycoprotein-2 (MAGP2) is an extracellular matrix protein that 76 
interacts with microfibril/elastin networks [4, 5] and mediates cell adhesion via it’s N-77 
terminal RGD domain [6].  In addition to a role in building elastin networks, MAGP2 is 78 
also a pro-angiogenic component of vascular microenvironments [7] and increased 79 
expression of MAGP2 has been associated with increased vascular densities and poor 80 
prognosis in ovarian cancers [8].  Beyond it’s structural role in the ECM, MAGP2 also 81 
functions as a matricellular protein by interacting with the Notch signaling cascade.  82 
Specifically, the C-terminal of MAGP2 interacts with the Notch ligand Jagged1 [9], and 83 
ultimately increases Notch signaling in COS-1 cells [10].  MAGP2 does not equally 84 
impact Notch signaling in all cell types however.  MAGP2 increases Notch signaling in a 85 
variety of non-endothelial cell lines, but consistently decreases Notch activation in 86 
several varieties of human and mouse endothelial cell lines [11].  It is the ability of 87 
MAGP2 to suppress Notch signaling in endothelial cells that imparts pro-angiogenic 88 
activity to MAGP2 [11].  However, the exact mechanism whereby MAGP2 promotes 89 
Notch signaling in some cell types, but blocks Notch signaling in endothelial cells has 90 
remained a mystery. 91 
 92 
Herein we show that the cell type-specific effect of MAGP2 on Notch signaling is 93 
independent of individual Notch receptor-ligand combinations but dependent on MAGP2 94 
interaction with RGD binding integrins. MAGP2 is not unique in this function however 95 
since we also found that the RGD domain of EGFL7 also controls Notch signaling.  On a 96 
larger scale, inhibition of integrin function with blocking antibodies or soluble RGD 97 
peptides also impacted Notch signaling activity.  Collectively, our results lead us to 98 
believe that MAGP2 and EGFL7 are just two of many ECM proteins that may indirectly 99 
control Notch via interactions with RGD binding integrins since.  Therefore, the broad 100 
implication of our results is the identification of a general signaling axis connecting 101 
cellular microenvironments (and the ECM proteins within these microenvironments) to 102 
Notch via integrin signaling. 103 
 104 
Results: 105 
 106 
MAGP2 suppresses Notch signaling in endothelial cells via interactions with RGD 107 
binding integrins 108 
 109 
We previously demonstrated that MAGP2 inhibits Notch signaling in endothelial cells 110 
but increases Notch signaling in non-endothelial cell lines [11].  Our first hypothesis to 111 
explain this observation was that MAGP2 may specifically inhibit receptor – ligand 112 
combinations present in endothelial cells, but promote receptor – ligand combinations 113 
present in non-endothelial cells.  Therefore, we used RT-PCR to compare expression of 114 
Notch receptors and ligands in SVEC endothelial cells and B16F0 melanoma cells in 115 
which MAGP2 had previously been shown to reduce or increase Notch signaling 116 
respectively [11].  As shown in figure 1A, both cell lines expressed Notch receptors 1, 3, 117 
and 4 and also shared expression of Notch ligands Jagged1 and 2 (JAG1, 2).  However, 118 
expression of Notch ligands Delta-like 1 and 3 (Dll1, 3) was restricted to B16F0 cells 119 
while expression of the Delta-like 4 (Dll4) Notch ligand was restricted to SVEC cells.  120 
Therefore, we transiently transfected 293T cells with combinations of Notch1 together 121 
with MAGP2 and either Dll1, Dll3, or Dll4 cDNAs and monitored Notch activation by 122 
western blot analysis of whole cell lysates with anti-VAL1744 antibodies that only 123 
recognize the activated N1ICD domain cleaved at the VAL1744 position by gamma-124 
secretase.  As shown in figure 1B, regardless of combination, co-transfected MAGP2 125 
cDNA decreased Notch activation independently of Notch receptor – ligand combination. 126 
 127 
Figure 1:  MAGP2 128 
suppresses Notch 129 
activation 130 
independently of 131 
ligand type.  (A) 132 
Expression patterns of 133 
Notch receptors and 134 
ligands in murine 135 
SVEC endothelial 136 
cells and B16F0 137 
melanoma cells.  Expression of Notch receptors and ligands was screened by RT-PCR with transcript 138 
specific oligos.  Non-reverse transcribed RNA (RT-) was used as a negative control to control for 139 
amplification from contaminating genomic DNA.  Shown are the results of a single experiment that was 140 
performed twice with identical results.  (B) Effect of MAGP2 on Notch activation by various Notch 141 
ligands.  293T cells were transfected with combinations of cDNA encoding Notch1, MAGP2, and various 142 
Notch ligands (JAG1, Dll1, Dll3, Dll4).  Notch activation was monitored by western blot analysis with 143 
anti-N1ICD (VAL-1744) specific antibodies.  Equivalent protein loading was monitored by stripping and 144 
re-blotting with anti-β-actin antibodies.  Shown is a representative result from a single experiment that was 145 
performed 6 times in it’s entirety. 146 
 147 
 148 
An alternative hypothesis to explain the cell type-specific regulation of Notch by MAGP2 149 
involved an unknown receptor protein for MAGP2 expressed in endothelial cells but not 150 
in non-endothelial cells.  Since MAGP2 contains an integrin binding RGD domain, we 151 
hypothesized that MAGP2 might bind to integrins present in endothelial cells but not 152 
non-endothelial cells and trigger a differential impact on Notch signaling.  To test this 153 
hypothesis, we transfected HMEC endothelial cells with a Notch responsive Hes-1 154 
luciferase construct plus MAGP2 cDNA and added increasing amounts of soluble RGD 155 
peptide to transfected cells to block activation of RGD binding integrins.  As shown in 156 
figure 2A and as previously observed [11], transfection of MAGP2 cDNA alone 157 
decreased Hes-1 promoter activity in HMEC cells.  The addition of soluble RGD peptides 158 
completely blocked the ability of MAGP2 to suppress Hes-1 promoter activity suggesting 159 
that MAGP2 decreases Hes-1 promoter activity by interacting with RGD binding 160 
integrins.  161 
 162 
To directly test if MAGP2 suppresses Hes-1 promoter activity in an RGD dependent 163 
manner, we used site directed mutagenesis to induce an RGDRGE mutation in 164 
MAGP2 and compared Hes-1 promoter activity in the presence of RGD and RGE 165 
versions of MAGP2.  The mutation was confirmed by sequence analysis (Fig 2B) and 166 
recombinant proteins were purified from bacterial cells by anti-FLAG chromatography 167 
(Fig 2C).  The functional outcome of the mutation was confirmed by comparing 168 
endothelial cell adhesion to RGD or RGE versions of the purified proteins.  Purified 169 
proteins were coated onto cell culture plates and remaining binding sites were blocked 170 
with BSA.  As anticipated, HMEC endothelial cells successfully adhered to both 171 
MAGP2-RGD and positive control fibronectin, but failed to adhere to MAGP2-RGE or 172 
BSA negative control indicating that the RGD domain is the sole binding site for HMEC 173 
endothelial cells on MAGP2  (Fig 2D).  HMEC cells were subsequently transfected with 174 
the Hes-1 luciferase reporter and either RGD or RGE versions of MAGP2 cDNAs to 175 
monitor Notch signaling activity.  As previously shown, MAGP2-RGD suppressed Hes-1 176 
promoter activity.  Surprisingly, MAGP2-RGE had a completely opposite effect and 177 
increased Notch signaling (Fig 2E).  This result demonstrated that ligation of RGD 178 
binding integrins by MAGP2 decreased Hes-1 promoter activity and that MAGP2 likely 179 
has both positive and negative Notch regulatory activities. 180 
 181 
Figure 2:  MAGP2 suppresses Notch 182 
activation in a RGD dependent manner.  183 
(A) Effect of MAGP2 and soluble 184 
RGD peptides on Hes-1 promoter 185 
activity.  Human HMEC endothelial 186 
cells were transfected with a Notch 187 
responsive Hes-1 luciferase reporter 188 
construct +/- MAGP2 cDNA then 189 
treated with increasing concentrations 190 
of soluble RGD peptide.  Hes-1 191 
promoter activity was monitored by 192 
luciferase expression in solubilized cell 193 
lysates.  The bar graph depicts data 194 
from n=5 independent experiments.  P-195 
values (compared to -MAGP2, -RGD 196 
control) were calculated by student’s t-197 
test.  (B) The RGD integrin binding 198 
domain of MAGP2 was mutated to a 199 
non-integrin binding RGE domain and 200 
verified by sequence analysis.  Note 201 
that the CGT to CGC change present in 202 
the R codon of the RGE mutant is 203 
silent.  (C) C-terminally FLAG tagged RGD (D) and RGE (E) versions of MAGP2 were expressed in 204 
BL21-DE3 cells and purified by anti-FLAG affinity chromatography.  Protein isolation was monitored by 205 
SDS-PAGE and coomassie staining.  (D) Effect of MAGP2-RGE mutation on cell adhesion.  206 
Recombinantly produced and purified RGD and RGE versions of MAGP2 were coated onto cell culture 207 
plates and cell adhesion was compared to positive control fibronectin, or negative control BSA.  (E) Effect 208 
of RGD and RGE versions of MAGP2 on Hes-1 promoter activity.  HMEC cells were transfected with 209 
either Hes-1 luciferase reporter alone, or in combination with either MAGP2-RGD or MAGP2-RGE and 210 
Notch activity was monitored in solubilized cell lysates.  The bar graph depicts data from n=4 experiments.  211 
The student’s t-test was used to calculate p-values compared to cells transfected with Hes1-luciferase alone 212 
and are indicated above their corresponding bars.   213 
 214 
Integrin function couples to Notch signaling activity. 215 
We found that the RGD domain of MAGP2 was essential for suppression of Notch in 216 
HMEC cells.  RGD domains are common throughout the extracellular matrix where they 217 
serve as binding sites for several types of integrins [2].  Therefore, it was important to 218 
determine if the RGD domain of MAGP2 was unique in it’s ability to control Notch.  219 
EGF-like domain-containing protein 7 (EGFL7) also contains an RGD domain that 220 
interacts with αvβ3 integrin [12] and has previously been shown to control Notch [13, 221 
14].  To determine if the RGD domain of EGFL7 also controls Notch signaling we 222 
compared Hes-1 promoter activity in HMEC cells transfected with RGD  RGE EGFL7 223 
mutants.  As shown in figure 3A, EGFL7-RGD significantly enhanced Hes-1 promoter 224 
activity compared to non-transfected cells.  RGD  RGE mutation of EGFL7 further 225 
increased Hes1 promoter activity suggesting that integrin ligation by EGFL7 decreases 226 
Notch1 signaling activity.   227 
To more broadly examine the role of integrin ligation in Notch signaling, we 228 
treated HMEC cells with soluble RGD peptides that bind RGD binding integrins but 229 
prevent integrin activation [15].  HMEC endothelial cells were incubated with increasing 230 
concentrations of soluble RGD peptides and accumulation of cleaved Notch1 NICD 231 
fragments was monitored in cell lysates by western blot with anti-VAL1744 antibodies.  232 
As shown in figures 3B and 3C, soluble RGD peptides dose-dependently caused a 233 
significant accumulation of N1ICD fragments.  Further western blot analysis suggested 234 
that activation of Notch signaling did not appear to obviously correlate with increased 235 
expression of either the full length Notch1 receptor, the Notch ligands Jagged1 or Dll4, or 236 
the VEGF receptor KDR.  Collectively, these findings demonstrated that generation of 237 
the N1ICD domain is regulated by RGD binding integrins and thus supported our 238 
hypothesis that the ECM may regulate Notch via interactions with RGD binding 239 
integrins. 240 
 241 
 242 
 243 
 244 
 245 
Figure 3:  RGD binding 246 
integrins control Notch.  247 
(A) The effect of EGFL7 248 
on Hes-1 promoter 249 
activity.  Empty vector (-250 
C), RGD or RGE 251 
versions of EGFL7 were 252 
co-transfected with Hes-253 
1 luciferase plasmid into 254 
HMEC cells and 255 
luciferase activity was 256 
monitored in whole cell lysates.  The data depict the average +/- SE of n=4 experiments.  P-values are 257 
indicated above their corresponding bars.  (B) The effect of soluble RGD peptides on N1ICD accumulation 258 
in HMEC cells.  HMEC cells were treated with increasing concentrations of soluble RGD peptides and 259 
N1ICD accumulation was monitored by western blot in fractionated whole cell lysates with anti-VAL1744 260 
antibodies.  Expression of full-length Notch1, Jagged1, Dll-4, and VEGFR2 (KDR), was monitored by 261 
subsequent stripping and re-blotting with specific antibodies.  Equivalent protein loading was monitored by 262 
blotting with anti-β-actin antibodies.  Shown are representative blots from a single experiment that was 263 
performed n=5 independent times.  (C) Image-J quantitation of N1ICD western blot data presented in panel 264 
B.  Bar graph depicts data from n=5 experiments.  P-values were calculated with the student’s t-test 265 
compared to untreated control cells and are indicated above their corresponding bars. 266 
 267 
β3 and β1 integrins control Notch signaling. 268 
At least eight of the 24 known integrin heterodimers have affinity for RGD motifs [2].  269 
Therefore, we used RT-PCR to compare expression of α and β integrin subunits known 270 
to heterodimerize into RGD binding integrins in HMEC cells [2].  HMEC cells expressed 271 
α2, α5, αV, β1, β3, and β6 subunits (Fig. 4A).  Both MAGP2 and EGFL7 had previously 272 
been shown to interact with αvβ3 integrins but not with β1 integrins [6, 12] leading to the 273 
hypothesis that β3 but not β1 integrins would interact with Notch signaling.  To test this 274 
hypothesis, we cultured HMEC endothelial cells in the presence of 0.5 to 2.0 µg/ml of β3 275 
or β1 blocking antibodies and used western blot analysis to monitor Notch activation via 276 
N1ICD fragment accumulation in whole cell lysates.  As shown in figure 4B and 4C, 7H2 277 
β3 blocking antibodies that had previously been shown to block β3 integrin mediated 278 
adhesion [16] dose-dependently enhanced N1ICD accumulation.  In contrast, P5D2 β1 279 
blocking antibodies that had previously been shown to block β1 integrin mediated 280 
adhesion [17] induced N1ICD accumulation at low dose (0.5 µg/ml), although higher 281 
concentrations of β1 blocking antibodies failed to significantly affect N1ICD 282 
accumulation.  We next transfected HMEC cells with the Hes-1 luciferase reporter and 283 
monitored Hes-1 promoter activity in the presence or absence of blocking antibodies 284 
directed against β3 or β1 integrins.  Interestingly, application of both β3 and β1 blocking 285 
antibodies dose-dependently increased Hes-1 promoter activity across all tested antibody 286 
concentrations (0.5 to 2.0 µg/ml) (Fig 4D).  Moreover, this activity was not restricted to 287 
the Hes-1 promoter since both β3 and β1 blocking antibodies also enhanced promoter 288 
activity from the Notch responsive Hes-5 and synthetic 4X-CSL promoters at 2.0 µg/ml 289 
(Fig 4E).  Since HMEC cells also expressed β6 integrin, we also examined HES-1 290 
promoter activity in the presence of 10D5 αvβ6 blocking antibodies but did not observe a 291 
significant change in reporter activity (data not shown). Collectively these results 292 
confirmed our hypothesis that β3 integrins couple to the Notch signaling pathway, and 293 
also suggested that β1 integrin couples to Notch signaling via a mechanism that has 294 
similarities, but may also have distinctions compared to β3 – Notch signaling. 295 
 296 
Figure 4: β3 and 297 
β1 integrins couple 298 
to Notch signaling.  299 
(A) Analysis of 300 
RGD binding α 301 
and β integrin 302 
subunits in HMEC 303 
endothelial cells.  304 
PCR analysis of 305 
reverse transcribed 306 
(RT+) or non-307 
reverse transcribed 308 
(RT-) RNA with sequence specific oligos was used to detect expression of various RGD binding integrin 309 
subunits or GAPDH as a control.  PCR products were resolved in PAGE gels and detected with ethidium 310 
bromide.  Shown are the results of a representative experiment that was performed twice with identical 311 
results.  (B) Effect of β3 and β1 blocking antibodies on N1ICD fragment accumulation in HMEC cells.  312 
HMEC endothelial cells were cultured in the presence of increasing concentrations of β3 or β1 blocking 313 
antibodies and N1ICD accumulation was monitored by western blot analysis of whole cell lysates with 314 
anti-VAL1744 specific antibodies. Protein loading was monitored by stripping and subsequent re-blotting 315 
with anti-vinculin antibodies.  Shown are the results of a single experiment from n=4 independent 316 
experiments.  (C) Image-J quantitation of data presented in panel B.  The bar graph depicts N1ICD pixel 317 
density from n=4 experiments.  The student’s t-test was used to calculate p-values compared to untreated 318 
HMEC cells and are indicated above their corresponding bars.  (D) Effect of β3 or β1 blocking antibodies 319 
on Hes-1 promoter activity.  HMEC endothelial cells were transfected with Hes-1 luciferase constructs and 320 
incubated in increasing concentrations of β3 or β1 blocking antibodies.  Notch signaling was monitored by 321 
measuring luciferase activity in solubilized cell lysates.  The bar graph depicts data from n=4 experiments.  322 
P-values compared to untreated cells were calculated using the student’s t-test and are indicated above 323 
corresponding bars.  (E) Comparison of β3 or β1 blocking antibodies effect on Hes-1, Hes-5, and 4X-CSL 324 
promoters.  HMEC cells were transfected with luciferase reporter vectors containing either Hes-1, Hes-5, or 325 
4X-CSL promoters and treated with 0 or 2µg/ml of β3 or β1 blocking antibodies.  The bar graph depicts 326 
data from n=4 experiments.  P-values compared to untreated cells were calculated with the student’s t-test 327 
and are indicated above their corresponding bars. 328 
 329 
Discussion: 330 
 331 
The original intent of this project was to explore the mechanistic basis by which MAGP2 332 
suppresses Notch signaling in endothelial cells but promotes Notch signaling in non-333 
endothelial cells.  The capacity of MAGP2 to differentially control Notch was originally 334 
hypothesized to be based on MAGP2 interactions with specific Notch receptor – ligand 335 
combinations present in endothelial cells but not in non-endothelial cells.  In testing this 336 
hypothesis, we observed differential expression of Notch receptors in endothelial (SVEC) 337 
and non-endothelial (B16F0) cells, but transplantation of these ligands and MAGP2 into 338 
293T cells did not suggest a differential ability of MAGP2 to regulate Notch1 activation 339 
by individual ligands (Fig 1).  Instead, mutation of the MAGP2 RGD domain to a non-340 
integrin binding RGE domain not only eliminated the ability of MAGP2 to suppress 341 
Notch signaling in endothelial cells, but also imbued MAGP2 with the ability to promote 342 
Notch signaling in endothelial cells (Fig 2).  Combining these results and the results of 343 
Miyamoto et al [10] which demonstrated that the C-terminal of MAGP2 is necessary to 344 
promote Notch signaling in 3T3 cells, we now hypothesize that MAGP2 controls Notch 345 
signaling with a two-part mechanism.  In cells expressing MAGP2 binding integrins (i.e. 346 
αvβ3), MAGP2 acts in a dominant negative fashion negating the pro-Notch signaling 347 
conferred by the MAGP2 C-terminal.  However in cells lacking MAGP2 binding 348 
integrins, the C-terminal of MAGP2 increases Notch through induced dissociation of the 349 
Notch extracellular domain as previously demonstrated [10].  Interestingly, MAGP2 is 350 
subject to cleavage by proprotein convertase near the C-terminal [18] raising the 351 
intriguing possibility that cleavage of MAGP2 (or other ECM proteins) may act as an 352 
additional level of regulatory activity.  A similar mechanism can also be envisioned for 353 
EGFL7.  In this case however, we found that EGFL7 increased Notch signaling and 354 
mutation of the RGD domain further increase Notch signaling.  These results suggest that 355 
EGFL7 may also contain both pro- and anti-Notch regulatory activity although it is not 356 
known if EGFL7 is subject to cleavage in the ECM. 357 
 358 
Although our original intent was to explore the mechanism by which MAGP2 controls 359 
Notch, our results have uncovered a mechanism that may be broadly applied to many 360 
ECM proteins that interact with integrins.  As such these results add a new dimension to 361 
the emerging idea that the cellular microenvironment via specific extracellular matrices is 362 
capable of controlling Notch signaling activity.  Other reports have also hinted at this 363 
possibility.  Weijers et al., [19] described an effect of low molecular weight fibronectin 364 
fragments on the expression of the Notch ligand Dll4 and subsequent Notch activation in 365 
endothelial cells.  More recently, Estrach et al., [20] and Stenzel et al., [21] demonstrated 366 
that laminin 111 and laminin α4 increase Dll4 expression in endothelial cells via α2β1 367 
and α6β1 integrins.  Stenzel et al., continued to show that disruption of this signaling 368 
system had dramatic complications for normal angiogenesis thus hinting at the biological 369 
significance of this signaling system [21].  While similar in some ways, our results are 370 
distinct since treatment of HMEC cells with soluble RGD peptides increased Notch 371 
signaling activity independently of Notch1, Jagged1, or Dll4 expression (Fig 3).  372 
Therefore, instead of controlling Notch signaling via increased Notch receptor or ligand 373 
expression, our results suggest that integrin ligation directly engages in cross-talk with 374 
Notch.  Support for this mechanism has been published elsewhere.  Suh et al., [22] 375 
demonstrated that collagen1 increases NICD accumulation via interactions with α2b1 376 
integrins, Mo et al., [23] observed that the downstream integrin regulator ILK (Integrin 377 
linked Kinase) decreases Notch signaling by stimulating ubiquitination and rapid 378 
degradation of the active Notch1 NICD fragment, and Ma et al., [24] found that the 379 
kinase domain of SRC binds to the ankyrin domain of active NICD.  Finally, a recent 380 
screen to find genetic interactions with Notch identified a signaling mechanism involving 381 
Notch, SRC, and JNK that was important for normal eye development in drosophila [25].  382 
Further investigation will be required to determine the mechanism by which integrins 383 
couple to Notch signaling, however it is worth noting that SRC and ILK are well known 384 
downstream effectors of integrins [3]. 385 
 386 
Our results not only suggest that integrins control Notch signaling, but that signaling 387 
through β1 and β3 integrins differentially controls Notch.  We found that blocking 388 
antibodies against β3 and β1 integrins both increased Hes-1, Hes-5, and 4X-CSL 389 
promoter activity while β3 but not β1 blocking antibodies dose-dependently increased 390 
N1ICD accumulation (Fig 4). While we don’t know how β3 and β1 integrins 391 
differentially control Notch, this observation is consistent with previous work showing 392 
that β1 and β3 integrins have both overlapping and independent mechanotransduction 393 
activities in cells [26-28].  Building on this idea is the fact that β1 and β3 ligands often 394 
have distinct spatiotemporal distributions in tissues. For instance, β1 ligands such as 395 
laminins and collagen 4 are enriched in angiostatic vascular basement membranes [29], 396 
while β3 ligands such as vitronectin, fibronectin, and fibrin are enriched in pro-397 
angiogenic provisional matrices [30].  Therefore, we speculate that diverse 398 
microenvironments differentially regulate Notch in response to cellular integrin 399 
expression profiles and the local extracellular matrix composition.   400 
 401 
Future experiments will need to determine the scope to which ECM proteins in the 402 
microenvironment influence angiogenesis through Notch signaling, but it is noteworthy 403 
that a number of ECM proteins have been shown to regulate Notch signaling and to 404 
interact with either β3 integrins (e.g. EGFL7 [12, 13] and MAGP2 [6, 7, 11] or with β1 405 
integrins (e.g. CCN3 [31, 32] and Reelin [33, 34]).  Finally, additional observations have 406 
demonstrated that Notch1 and β1 integrin co-localize in neural stem cells [35] and that 407 
activation of Notch signaling can control β1 integrin affinity [36, 37] suggesting the 408 
existence of a feedback loop that coordinates Notch and integrin function. Collectively, 409 
our observations combined with other results suggest the presence of an ECM – integrin 410 
– Notch signaling axis that may represent an important mechanism enabling cells to 411 
respond to their microenvironment.  412 
 413 
In conclusion, through basic research aimed at understanding how MAGP2 controls 414 
Notch signaling, we have arrived at a more universal understanding of how ECM 415 
molecules in the cellular microenvironment impact cell physiology via integrin ligation 416 
and subsequent manipulation of the Notch signaling pathway. 417 
 418 
Materials and Methods: 419 
 420 
Plasmids 421 
 422 
The pcDNA3.1 myc-his tagged MAGP2 expression construct was previously described 423 
[7] and was subjected to site-directed mutagenesis with mutagenic oligos to produce the 424 
MAGP2-RGE construct.  The EGFL7 expression plasmid was constructed by gateway 425 
cloning a human EGFL7 cDNA (clone ID# 30400137) that had been amplified by PCR 426 
with oligos that added 5’ Kozak sequence and 3’FLAG tag, cloned into pcDNA-DEST40, 427 
and sequenced in its entirety.  Mutagenesis of the EGFL7 expression construct was 428 
performed by site-directed mutagenesis with mutagenic oligos and mutants were 429 
identified by sequence analysis.  The Myc-tagged mammalian expression vectors 430 
encoding murine Notch1 (pCS2+mN1FL6MT) and Jagged-1 (pCS2+Jag1-6MT) were 431 
kindly provided by Dr. Raphael Kopan (Washington University, St. Louis, MO).  The 432 
Delta-like 1 (Dll1) and Delta-like 3 (Dll3) expression constructs were kindly provided by 433 
Dr. Geraldine Weinmaster (UCLA, Los Angles, CA).  The Delta-like 4 (Dll4) expression 434 
construct was cloned by PCR amplification of murine Dll4 cDNA (clone ID# 86280 with 435 
oligos that introduced 5’ kozak and EcoR1 sequences, and 3’ SacII sequence.  The PCR 436 
product was ligated into pcDNA3.1 Myc-his and sequenced in it’s entirety.  The Hes1 437 
and Hes5-luciferase reporters were purchased from Addgene and consist of nucleotides -438 
467 to +46 and -800 to +73 relative to the transcriptional start sites respectively.  The 4X-439 
CSL luciferase construct was also purchased from Addgene and consists of 4 tandem 440 
repeats of the high affinity CSL binding sites ( 5’CGTGGGAA3’). 441 
 442 
Luciferase assays 443 
 444 
For experiments examining the effect of RGD peptides, or WT vs RGE MAGP2/EGFL7 445 
cDNAs on Hes-1 promoter activity, HMEC cells were seeded into 24-well plates at a 446 
density of 25,000 cells/well and transfected the following day with LT-1 liposomes 447 
containing various combinations of Hes-1 luciferase (200ng/well), MAGP2/EGFL7 448 
cDNAs (WT or RGE) (100ng/well), and CMV-β-gal control plasmid (10ng/well). Where 449 
appropriate, cells were treated with 1, 10, or 100 µg/ml of soluble RGD 450 
(GCGYGRGDSPG) peptide (GenScript, Piscataway, NJ).  48 hours after transfection, 451 
cells were lysed in passive lysis buffer (Promega, Madison, WI) and luciferase and β-gal 452 
activities were measured on a Glo-Max luminometer.  In experiments with β3 and β1 453 
blocking antibodies, HMEC cells were transfected by electroporating 2,000,000 cells in 454 
PBS with 1.9 µg of luciferase reporter (Hes-1, Hes-5, or 4X-CSL luciferase) and 0.1 µg 455 
of CMV-β-gal reporter.  Cells were pulsed in a nucleofector 2b (Lonza, Walkersville, 456 
MD) electroporator (2mm gap) set for “HUVEC”, diluted into EGM2 growth media, and 457 
plated into 12 wells of a 24-well plate (250 µl/well) to which 0, 0.5, 1, or 2 µg/ml of β3 458 
(7H2) or β1 (P5D2) blocking antibodies (Developmental Studies Hybridoma Bank, Iowa 459 
City, IA) were immediately added.  Electroporated cells were collected 24 hours later and 460 
luciferase activity was measured as previously described [38]. 461 
 462 
Reverse transcription PCR 463 
 464 
Total RNA was extracted from cultured cells using Ribosol (Amresco, Solon, OH) and 465 
iScript reverse transcriptase (Bio-Rad, Hercules, CA) was used to generate cDNA pools 466 
from 1µg of total RNA.  RT-PCR reactions were performed using 12.5ng of cDNA, 467 
0.8uM each oligo, 200 µM dNTP, 1x standard buffer, and 2 units Taq Polymerase in a 468 
total reaction volume of 25 µl. Cycling parameters were as follows: 1 cycle at 94oC for 2 469 
min; 25 cycles at 94oC for 45 sec, 55oC for 30 sec, and 72oC for 30 sec.  Oligonucleotide 470 
sequences are reported in table 1. 471 
 472 
Recombinant protein and adhesion assay 473 
 474 
The bacterial pSBET MAGP2 expression vector was previously described [7].  The 475 
MAGP2 RGE mutant vector was constructed by site-directed mutagenesis of wild-type 476 
MAGP2 as described above.  Recombinant MAGP2 proteins were expressed in BL21-477 
DE3 E. coli cells and purified from sonicated cell lysates by affinity chromatography on 478 
FLAG-M2 monoclonal antibody columns (Sigma, St. Louis, MO).  Bound proteins were 479 
washed initially with 10 column volumes of TBS/0.1% Triton X-100, followed by an 480 
additional 20 column volumes of TBS.  Afterward, recombinant proteins were eluted by 481 
addition of 2.5 column volumes of FLAG M2 peptide (100 g/ml), which subsequently 482 
was concentrated by centrifugation in 5 kD centricon devices (Sartorius, Goettingen, 483 
Germany). 484 
 485 
Antibodies 486 
 487 
Antibodies against Notch1 (#3608), Jagged1 (#2620), Dll4 (#2589), N1ICD (VAL1744, 488 
#2421), and KDR (VEGFR2) (#2472) were purchased from Cell Signaling Technologies 489 
(Danvers, MA).  The 7H2 β3 blocking antibodies and P5D2 blocking antibodies were 490 
previously described [16, 17] and purchased as monoclonal supernatants from the 491 
Developmental Studies Hybridoma Bank (Iowa City, Iowa).  Anti-β Actin antibodies (sc-492 
130656) and anti-Vinculin antibodies (sc-5573) were purchased from Santa Cruz (Paso 493 
Robles, CA). 494 
 495 
 496 
 497 
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Table 1:  Oligonucleotides used in this study. 640 
Oligo Name Oligo Use Oligo sequence 
AA37 Mouse GAPDH fwd RT-PCR GACAATGAATACGGCTACAGCAAC 
AA38 Mouse GAPDH rev RT-PCR GTGCAGCGAACTTTATTGATGGTA 
AA11 Mouse Notch1 fwd RT-PCR TGCACCTGCTGTCATCTCTGACTT 
AA12 Mouse Notch1 rev RT-PCR AGGATCAGTGGAGTTGTGCCATCA 
AA13 Mouse Notch3 fwd RT-PCR AGCTGTGTCAGGAAGGTGGAAAGT 
AA14 Mouse Notch3 rev RT-PCR AACAGAGATAGCGGGCCACAAGAT 
AA17 Mouse Dll3 fwd RT-PCR TGTGAAGAGCCTGATGAATGCCGT 
AA18 Mouse Dll3 rev RT-PCR ACCTCACATCGAAGCCCGTAGAAT 
AA19 Mouse Dll4 fwd RT-PCR ACTCACCACTCTCCGTGCAAGAAT 
AA20 Mouse Dll4 rev RT-PCR TATGCTCACAGTGCTGGCCATAGT 
AA21 Mouse Dll1 fwd RT-PCR AATCTGTCTGCCAGGGTGTGATGA 
AA22 Mouse Dll1 rev RT-PCR TGCACGGCTTATGGTGAGTACAGT 
AA23 Mouse Notch4 fwd RT-PCR TGAAGGGCCACACTGTGAGAAAGA 
AA24 Mouse Notch4 rev RT-PCR ACACACACACAAGGATCTCTGGCA 
AA25 Mouse JAG2 fwd RT-PCR TAGCAAGGTATGGTGCGGATGGAA 
AA26 Mouse JAG2 rev RT-PCR GTCGGGCACAGTTGTTGTCCAAAT 
AA28 Mouse JAG1 fwd RT-PCR TGCTGAGCATGCTTGTCTCTCTGA 
AA29 Mouse JAG1 rev RT-PCR CAAGGTTTGGCCTCGCACTCATTT 
AA103 Human GAPDH fwd RT-PCR TCCATGACAACTTTGGTATTCGT 
AA104 Human GAPDH rev RT-PCR AGTAGAGGCAGGGATGATGTT 
KW181 Human Int α2 fwd RT-PCR TCTCAGAAGTCTGTTGCCTGCGAT 
KW182 Human Int α2 rev RT-PCR ACTGATGTCACCAGCCTTGTCTGT 
KW183 Human Int α5 fwd RT-PCR TCGAGACAAACTCTCGCCGATTCA 
KW184 Human Int α5rev RT-PCR TCACGGCAAAGTAGTCACAGCTCA 
KW185 Human Int αV fwd RT-PCR AAGATGTTGGGCCAGTTGTTCAGC 
KW186 Human Int αV rev RT-PCR AGCAACTCCACAACCCAAAGTGTG 
KW187 Human Int β1 fwd RT-PCR TCTGCGGACAGTGTGTTTGTAGGA 
KW188 Human Int β1 rev RT-PCR AATGGGACACAGGATCAGGTTGGA 
KW189 Human Int β3 fwd RT-PCR CCCACTTGGCATCATTCACAGCAA 
KW190 Human Int β3 rev RT-PCR AAGAGACCTTCAAGACTGGCTGCT 
AK366 Human Int β8 fwd RT-PCR AGCAAATTGGCAGGCATAGTGGTG 
AK367 Human Int β8 rev RT-PCR TCGTCACGTTTCTGCATCCTTCCA 
AK368 Human Int β6 fwd RT-PCR AGCAAATTGGCAGGCATAGTGGTG 
AK369 Human Int β6 rev RT-PCR AGACATCTCTTTGGAAAGCCGGGA 
AK370 Human Int α8 fwd RT-PCR AAGGGATTTCGACCACTGAGCTGT 
AK371 Human Int α8 rev RT-PCR ACTCCTCTTATTTCCACCTGCGCT 
AA953 Mouse MAGP2 RGE mutagenesis GTGAATGTCTCAGGCACATCCTCTCCA 
CGTTGACCACTGAC 
AA952 Mouse MAGP2 RGE mutagenesis GTCAGTGGTCAACGTGGAGAGGATGTGCCT 
GAGACATTCAC 
PD424 hEGFL7 RGE mutagenesis GGATGGCGGGGTGAGACTTGCCAGTCAGATG 
PD425 hEGFL7 RGE mutagenesis CATCTGACTGGCAAGTCTCACCCCGCCATCC 
AA39 Mouse DLL4 fwd cloning GGCGGCGAATTCACCATGGCGGCAG 
CGTCCCGG 
AA6 Mouse DLL4 rev cloning GGCGGCCCGCGGTACCTCCGTGGCAATGAC 
 641 
